Table 3.
Comparison of brentuximab vedotin for relapsed or refractory aggressive non-Hodgkin lymphoma
| Variable | DLBCL [6] | PTCL [7] | PMBCL [8] | Present study |
|---|---|---|---|---|
| No. | 49 | 35 | 15 | 33 |
| Age (yr) | 62 (17-85) | 64 (33-83) | 29 (19-73) | 56 (27-73) |
| DLBCL-NOS | 43 | - | - | 12 |
| EBV-positive DLBCL | 5 | - | - | - |
| T-cell–rich B cell | 1 | - | - | - |
| PMBCL | - | - | 15 | 3 |
| PTCL | - | 22 | - | 8 |
| AITL | - | 13 | - | 1 |
| ENKTL | - | - | - | 7 |
| Transformed MF | - | - | - | 2 |
| ECOG PS 0/1 | 45 (91.8) | 30 (85.7) | Not reported | 33 (100) |
| CD30+ cell | 25 (0-100) | Not reported | Not reported | 30 (30-100) |
| Stage III/IV | 35 (71.4) | 27 (77.1) | 8 (53.3) | 26 (79) |
| Refractory to most recent prior therapy | 40 (81.6) | 22 (62.8) | 11 (73.3) | 22 (67) |
| No. of previous treatments | 3 (1-6) | 2 (1-9) | 3 (1-4) | 3 (2-10) |
| Previous ASCT | 10 (20.4) | 3 (9) | 8 (53) | 7 (21.2) |
| Disease control rate | 32/48 (66.7) | 20/34 (58.8) | 3/15 (20.0) | 16/33 (48.4) |
| Objective response rate | 21/48 (43.7) | 14/34 (41.1) | 2/15 (13.3) | 12/33 (36.3) |
| CR rate | 8/48 (16.7) | 8/34 (23.5) | 0 | 6/33 (18.1) |
| Progression-free survival (mo) | 4.0 (0.6-24) | 2.6 (not reported) | - | 1.9 (0.4-35.0) |
| Duration of response (mo) | 5.6 (0.0-22.7) | 7.6 (1.3-14) | < 3-4 | 6.0 (3.9-35.0) |
| Duration of complete response (mo) | 16.6 (2.7-22.7) | Not reported | - | 11.3 (4.5-35.0) |
Values are presented as median (range) or number (%). DLBCL, diffuse large B-cell lymphoma; PTCL, peripheral T-cell lymphoma; PMBCL, primary mediastinal large B-cell lymphoma; NOS, not otherwise specified; EBV, Epstein-Barr virus; AITL, angioimmunoblastic T-cell lymphoma; ENKTL, extranodal NK/T-cell lymphoma; MF, mycosis fungoides; ECOG PS, Eastern Cooperative Oncology Group performance status; ASCT, autologous stem cell transplantation; CR, complete response.